Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 89Daunorubicin 45Azacitidine 43Idarubicin 27venetoclax 26fludarabine 26Etoposide 25Cyclophosphamide 25Mitoxantrone 22Decitabine 19Busulfan 19Methotrexate 16Gemtuzumab 14Granulocyte Colony-Stimulating Factor 12Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10gilteritinib 9Filgrastim 9fludarabine phosphate 8Tacrolimus 8Mycophenolic Acid 8Cyclosporine 8Tretinoin 7Radiotherapy 7Drug Therapy 7Observation 6Homoharringtonine 6Antilymphocyte Serum 6quizartinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myeloid, Acute × lintuzumab × Clear all
NCT00006045 2013-11-06

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 3 Unknown
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡